GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes
Authors
Keywords
-
Journal
Journal of Diabetes Research
Volume 2018, Issue -, Pages 1-12
Publisher
Hindawi Limited
Online
2018-04-03
DOI
10.1155/2018/4020492
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
- (2017) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Current perspectives on cardiovascular outcome trials in diabetes
- (2016) Oliver Schnell et al. Cardiovascular Diabetology
- Effects of Liraglutide on Reperfusion Injury in Patients With ST-Segment–Elevation Myocardial InfarctionCLINICAL PERSPECTIVE
- (2016) Wei Ren Chen et al. Circulation-Cardiovascular Imaging
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Glucagon-like Peptide-1 Receptor Agonists on Lipid Profiles Among Type 2 Diabetes: A Systematic Review and Network Meta-analysis
- (2015) Feng Sun et al. CLINICAL THERAPEUTICS
- Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis
- (2015) Feng Sun et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- (2015) Xavier Pi-Sunyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Actions of Incretin-Based Therapies
- (2014) John R. Ussher et al. CIRCULATION RESEARCH
- HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin
- (2014) Bo Ahrén et al. DIABETES CARE
- Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3)
- (2014) Guillermo Umpierrez et al. DIABETES CARE
- Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)
- (2014) Carol Wysham et al. DIABETES CARE
- Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)
- (2014) Michael Nauck et al. DIABETES CARE
- Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5
- (2014) P. D. Home et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled
- (2014) J. Reusch et al. DIABETES OBESITY & METABOLISM
- Glycemic Variability and Oxidative Stress: A Link between Diabetes and Cardiovascular Disease?
- (2014) Yoshifumi Saisho INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Cardioprotective Effects of Exenatide in Patients With ST-Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
- (2013) Jong Shin Woo et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Efficacy and Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin (GetGoal-M)
- (2013) Bo Ahrén et al. DIABETES CARE
- Economic Costs of Diabetes in the U.S. in 2012
- (2013) DIABETES CARE
- Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P)
- (2013) M. Pinget et al. DIABETES OBESITY & METABOLISM
- Diabetes mellitus tipo 2: nuevos tratamientos
- (2013) Juan F. Ascaso MEDICINA CLINICA
- Epidemiología de la insuficiencia cardiaca en España en los últimos 20 años
- (2013) Inés Sayago-Silva et al. REVISTA ESPANOLA DE CARDIOLOGIA
- Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis
- (2013) Louise E Robinson et al. BMJ Open
- Update on incretin hormones
- (2012) Liza K. Phillips et al. Annals of the New York Academy of Sciences
- Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy: A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)
- (2012) V. A. Fonseca et al. DIABETES CARE
- Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme
- (2012) K. Niswender et al. DIABETES OBESITY & METABOLISM
- Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial
- (2012) Baptist Gallwitz et al. LANCET
- A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model
- (2011) Tracey Gaspari et al. Diabetes & Vascular Disease Research
- Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Di@bet.es Study
- (2011) F. Soriguer et al. DIABETOLOGIA
- Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction
- (2011) Jacob Lønborg et al. EUROPEAN HEART JOURNAL
- Unknown
- (2011) Ling Li et al. MOLECULAR MEDICINE
- Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
- (2010) Richard M Bergenstal et al. LANCET
- Effects of Exenatide on Systolic Blood Pressure in Subjects With Type 2 Diabetes
- (2009) T. Okerson et al. AMERICAN JOURNAL OF HYPERTENSION
- Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
- (2009) B. Zinman et al. DIABETES CARE
- Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
- (2009) D. Russell-Jones et al. DIABETOLOGIA
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
- (2009) John B Buse et al. LANCET
- Oscillating Glucose Is More Deleterious to Endothelial Function and Oxidative Stress Than Mean Glucose in Normal and Type 2 Diabetic Patients
- (2008) A. Ceriello et al. DIABETES
- Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
- (2008) M. Nauck et al. DIABETES CARE
- The target cell response to cytokines governs the autoreactive T cell repertoire in the pancreas of NOD mice
- (2008) M. Hultcrantz et al. DIABETOLOGIA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now